Managing hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulness

Therapeutic Advances in Chronic Disease
Yoram YagilCollaborative Study Group

Abstract

Ferric citrate is a novel phosphate binder that allows the simultaneous treatment of hyperphosphatemia and iron deficiency in patients being treated for end-stage renal disease with hemodialysis (HD). Multiple clinical trials in HD patients have uniformly and consistently demonstrated the efficacy of the drug in controlling hyperphosphatemia with a good safety profile, leading the US Food and Drug Administration in 2014 to approve its use for that indication. A concurrent beneficial effect, while using ferric citrate as a phosphate binder, is its salutary effect in HD patients with iron deficiency being treated with an erythropoietin-stimulating agent (ESA) in restoring iron that becomes available for reversing chronic kidney disease (CKD)-related anemia. Ferric citrate has also been shown in several studies to diminish the need for intravenous iron treatment and to reduce the requirement for ESA. Ferric citrate is thus a preferred phosphate binder that helps resolve CKD-related mineral bone disease and iron-deficiency anemia.

References

Dec 1, 1989·Kidney International·D P FromentA C Alfrey
Dec 1, 1989·Kidney International·B A MolitorisA C Alfrey
Oct 1, 1989·Kidney International·M L MaiJ S Fordtran
Jan 1, 1987·Contributions to Nephrology·F L Van de VyverM E De Broe
May 1, 1969·Archives of Internal Medicine·N S BrickerL V Avioli
Mar 20, 1999·Kidney International. Supplement·I C Macdougall
Jun 11, 1999·Journal of the American Society of Nephrology : JASN·C H HsuE W Young
Jan 6, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·G R BailieN A Mason
Jan 29, 2002·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Wu-Chang YangChen H Hsu
Sep 19, 2007·Expert Opinion on Emerging Drugs·Guido BellinghieriVincenzo Savica
May 16, 2008·Journal of the American Society of Nephrology : JASN·Gérard M LondonMarie-Christine de Vernejoul
Nov 13, 2008·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Adrian CovicDavid Goldsmith
Dec 19, 2008·Journal of the American Society of Nephrology : JASN·Tamara IsakovaMyles Wolf
Nov 26, 2009·Journal of Renal Care·Csaba P Kovesdy, Kamyar Kalantar-Zadeh
Mar 17, 2011·Advances in Chronic Kidney Disease·Donald A Molony, Brett W Stephens
Sep 7, 2011·Nature Reviews. Nephrology·Alastair J HutchisonPaul E C Brenchley
Jun 19, 2012·Hemodialysis International·Kausik UmanathUNKNOWN Collaborative Study Group
Oct 19, 2012·Nephron. Clinical Practice·Marvin SinsakulUNKNOWN Collaborative Study Group
Feb 2, 2013·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Jamie P DwyerUNKNOWN Collaborative Study Group
Apr 30, 2013·Drugs·Fabio Malberti
Aug 6, 2013·Journal of Renal Care·Iain Wittwer
Jan 1, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Keitaro YokoyamaHideki Hirakata
Jan 11, 2014·Clinical Journal of the American Society of Nephrology : CJASN·Keitaro YokoyamaGeoffrey A Block
Apr 9, 2014·BMC Nephrology·Wei Chen, Matthew K Abramowitz
May 20, 2014·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Keitaro YokoyamaHideki Hirakata
Jul 26, 2014·Journal of the American Society of Nephrology : JASN·Julia B LewisUNKNOWN Collaborative Study Group
Oct 17, 2014·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Cheryl A Thompson
Nov 18, 2014·Nephron. Clinical Practice·Keitaro YokoyamaHideki Hirakata
Dec 4, 2014·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Geoffrey A BlockGlenn M Chertow
Feb 19, 2015·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Jürgen FloegeUNKNOWN Sucroferric Oxyhydroxide Study Group
Mar 31, 2015·Clinical Kidney Journal·Armando Luis Negri, Pablo Antonio Ureña Torres
Apr 9, 2015·Clinical Kidney Journal·Andrea Galassi, Mario Cozzolino

❮ Previous
Next ❯

Citations

Apr 6, 2018·Cell Discovery·Hongbin WangGuangxun Meng
Jul 21, 2017·Basic & Clinical Pharmacology & Toxicology·Wander Barros do CarmoHelady Sanders-Pinheiro
Apr 17, 2017·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Meredith A Atkinson, Bradley A Warady
Oct 5, 2017·Journal of Nephrology·Charat ThongprayoonStephen B Erickson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.